Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer. – Brinkwire
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
Noosa News22 hours agoFarmers call for policy reform across multiple sectors as productivity collapses
-
General23 hours agoStar Wars’ fascist dystopia has never felt closer than in new season of Andor
-
Noosa News22 hours agoQueensland Premier David Crisafulli keeps clear of Coalition chaos in Canberra
-
Noosa News18 hours agoTrump’s trade war puts Australian beef centre stage in Shanghai